Building the Foundation for Modern Medicine: Our Series B Investment in Forus
Summary
- The healthcare delivery system fails to keep pace with scientific progress, causing treatment delays due to manual administrative burdens.
- Forus was founded to automate the entire prescription-to-fulfillment workflow using an AI platform that replaces manual forms & calls.
- The platform automatically identifies approval paths for providers & provides patients with visibility into medication access & affordability.
- Forus reports 10x annual provider growth for two consecutive years driven entirely by word of mouth.
- The company operates as an "AI 2.0" entity where the product is free for patients & providers to maximize network value.
- Forus functions as a flywheel where processing more prescriptions improves the system & generates insights for life sciences partners.
- Five of the top ten pharmaceutical companies currently partner with Forus to optimize drug investment & market efficiency.
- Founder Sahir Jaggi previously led product at Oscar Health & assembled a team of engineers, AI researchers, & healthcare veterans.
- Accel is leading Forus's Series B financing round alongside investors Thrive & General Catalyst.
Forus is building an AI-powered healthcare platform that automates the prescription-to-fulfillment process, helping patients access life-saving medications faster while reducing administrative burden for providers and life sciences companies.